[SCHEDULE 13D/A] Silence Therapeutics Plc American Depository Share SEC Filing

Rhea-AI Filing Summary

Silence Therapeutics Plc (SLN) – Schedule 13D/A Amendment No. 9

The filing discloses the updated beneficial ownership of long-time shareholder Richard Ian Griffiths and several Jersey-based entities he controls. After recent open-market activity and an increase in the company’s share capital, Mr. Griffiths now reports 34,543,302 ordinary shares (held directly and through seven entities), representing 24.4 % of SLN’s 141,690,849 outstanding shares. Voting and dispositive power for all shares is held solely by Mr. Griffiths.

Recent transactions: Between 8 May 2025 and 24 Jun 2025, Mr. Griffiths purchased an additional 543,581 ADSs on the open market for a combined cash consideration of US $2.7 million; each ADS equals three ordinary shares. These purchases were funded with personal or affiliated-company cash.

Entity breakdown:

• Ora Capital Ltd – 19,221,525 ordinary shares (13.6 %)
• Sarossa Plc – 1,815,522 shares
• Cream Capital Ltd – 3,967,896 shares
• Blake Holdings Ltd – 300,000 shares
• Ora Ventures Ltd – 360,000 shares
• Pinkey’s Ltd – 190,500 shares
• Direct holding – 8,687,859 shares

The amendment notes that the percentage ownership has changed because of both the incremental ADS purchases and dilution stemming from a recent increase in the Issuer’s share capital. No new contracts, voting agreements or other material relationships were reported, and a standard joint-filing agreement is included as an exhibit.

Positive

• Insider accumulation: Richard Griffiths purchased 543,581 ADSs for US $2.7 million during May–June 2025, indicating continued confidence.
• Significant holding maintained: Post-transaction ownership stands at 24.4 % of outstanding shares, underscoring sustained long-term commitment.

Negative

• Dilution effect: Percentage ownership declined due to an increase in Silence Therapeutics' share capital, signalling potential dilution for all shareholders.

Insights

Securities Analyst

TL;DR – Large insider adds US$2.7 m of SLN stock, lifting stake to 24.4 %; signals continued confidence, moderately positive.

The amendment confirms that Richard Griffiths, already SLN’s largest holder, increased exposure by purchasing 543,581 ADSs in May–June 2025. Despite dilution from new share issuance, his ownership remains substantial at 24.4 %. Insider buying of this magnitude (≈US$2.7 m) often supports market sentiment and reduces free float. No leverage or complex financing was used, limiting balance-sheet risk. While the filing does not disclose SLN’s reasons for issuing new shares, the net effect is a modestly positive indicator that a sophisticated investor continues to back the company.

Corporate Governance Expert

TL;DR – Ownership concentration persists; dilution trims percentage but still above 20 %, governance influence unchanged.

Mr. Griffiths and his controlled entities retain sole voting and dispositive power over more than one-fifth of SLN’s equity, preserving significant governance leverage. The incremental ADS purchases reinforce this position. The filing also highlights an increase in authorised share capital, diluting existing holders—an area investors may scrutinise for future capital-raising discipline. No shareholder agreements or change-of-control intentions are disclosed, keeping the amendment procedural. Overall impact on governance dynamics is neutral: concentration remains high, and no new control mechanisms are introduced.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 9)

Silence Therapeutics Plc

(Name of Issuer)

Ordinary Shares, nominal value of GBP0.05 per share

(Title of Class of Securities)

G8128Y157

(CUSIP Number)

Richard Griffiths
Floor 1 Liberation Station, Esplanade
St Helier, Y9, JE2 3AS
44-1534-719761

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/25/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. G8128Y157

1

Name of reporting person

Richard Ian Griffiths

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 34,543,302.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 34,543,302.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

34,543,302.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

24.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

* Consists of (i) 19,221,525 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 1,815,522 ordinary shares represented by ADSs held by Sarossa Plc; (iii) 3,967,896 ordinary shares represented by ADSs held by Cream Capital Limited; ; (iv) 300,000 ordinary shares represented by ADSs held by Blake Holdings Limited; (v) 360,000 ordinary shares represented by ADSs held by Ora Ventures Limited; (vi) 190,500 ordinary shares represented by ADSs held by Pinkey's Limited; and (vii) 8,687,859 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc and Cream Capital Limited and a controlling shareholder of Pinkey's Limited and possesses the power to direct the voting and disposition of these shares. **This percentage is calculated based upon the 141,690,849 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

SCHEDULE 13D

CUSIP No. G8128Y157

1

Name of reporting person

Ora Capital Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 19,221,525.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 19,221,525.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

19,221,525.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

13.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

* Consists of 19,221,525 ordinary shares represented by ADSs held by Ora Capital Limited. **This percentage is calculated based upon the 141,690,849 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, nominal value of GBP0.05 per share
(b)	Name of Issuer: Silence Therapeutics Plc
(c)	Address of Issuer's Principal Executive Offices: 72 Hammersmith Road, London, UNITED KINGDOM , W14 8TH.
Item 1 Comment: This Amendment No. 9 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025 and May 8, 2025 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value GBP0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect the open market transactions of the Issuer's ADSs by the Reporting Person together with dilution as a result of an increase in the share capital of the Issuer. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D.
Item 2.	Identity and Background
(a)	Richard Griffiths
(b)	Floor 1 Liberation Station, Esplanade, St Helier, Jersey, JE2 3AS
(d)	m/a
(e)	n/a
(f)	Jersey, Channel Islands
Item 3.	Source and Amount of Funds or Other Consideration
	Mr. Griffiths purchased an aggregate of 543,581 ADSs in open market transactions between May 8, 2025 and June 24, 2025 for an aggregate price of $2.7M. All purchases were for cash and were funded by companies or personal funds of Mr. Griffiths.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	n/a
Item 7.	Material to be Filed as Exhibits.
	A. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. B. Schedule 1 Transactions in ADSs During the Past Sixty Days

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Richard Ian Griffiths

Signature:	/s/ Richard Ian Griffiths
Name/Title:	Richard Ian Griffiths
Date:	06/25/2025

Ora Capital Limited

Signature:	/s/ Richard Ian Griffiths
Name/Title:	Director
Date:	06/25/2025

FAQ

How many Silence Therapeutics (SLN) shares does Richard Griffiths now own?

34,543,302 ordinary shares, equal to 24.4 % of the company’s 141.7 million shares outstanding.

What recent purchases were disclosed in the Schedule 13D/A?

Griffiths bought 543,581 ADRs between 8 May 2025 and 24 Jun 2025 for about US $2.7 million in cash.

Which entity holds the largest portion of Griffiths’ SLN stake?

Jersey-based Ora Capital Limited holds 19,221,525 ordinary shares, representing 13.6 % of the company.

Did the filing report any new shareholder agreements or contracts?

No. The amendment states no new contracts or arrangements other than a standard joint-filing agreement.

Why did Griffiths’ percentage ownership change?

The change reflects new ADS purchases and dilution from an increase in SLN’s share capital.